

Special Issue

Poly-Pharmacological Effects and Mechanisms of Phytochemicals

Message from the Guest Editor

Phytochemicals hold immense potential for developing treatments for various diseases, as evidenced by compounds like artemisinin, celastrol, and berberine. Their poly-pharmacological properties, which allow them to target multiple diseases, have garnered growing interest. For example, while artemisinin was initially used to treat malaria and helminth infections, recent research has demonstrated its potential for treating liver diseases, neurological disorders, immune dysfunctions, and cancer. This versatility raises important questions: Are there more undiscovered uses for these compounds, and what makes them so broadly effective? We invite researchers and authors in this field to contribute original research or review articles for this Special Issue. The goal is to showcase the vast array of bioactive compounds (with defined molecular compound) derived from natural sources and their critical role in modern drug discovery. Submissions focusing on novel applications of phytochemicals, the mechanisms underlying their poly-pharmacological effects, and updates on well-studied compounds are highly encouraged.

Guest Editor

Dr. Jiawen Shou

School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA

Deadline for manuscript submissions

31 May 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/221782

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).